Articles related to AMD/MACULAR DEGENERATION

Bausch + Lomb launched PreserVision AREDS3, a reformulation of its established AREDS2 supplement adding a proprietary B-vitamin complex, citing a narrative review of more than 20 human studies linking B-vitamin supplementation to reduced AMD risk.

Two retina specialists debated whether LIGHTSITE III evidence supports photobiomodulation as treatment for intermediate dry AMD, weighing modest BCVA gains against natural visual acuity variability, study quality concerns, and FDA authorization status.

OCT angiography revealed subclinical retinal and choroidal blood flow changes that correlated with disease severity across diabetic retinopathy, AMD, and central serous retinopathy in cited studies.

CPT code 0936T became active in January 2025 for retinal photobiomodulation, with reimbursement determined claim-by-claim and scope-of-practice limits restricting who may perform the procedure.

FDA approval of 20‑week dosing for Eylea HD offers eligible wAMD and DME patients the potential for fewer injections while maintaining long‑term visual outcomes.

“Axpaxli is the first and only investigational product in wet AMD with a novel mechanism of action to successfully demonstrate superiority to an approved anti-VEGF agent since their initial approval more than 20 years ago.” — Pravin U. Dugel, MD, Ocular Therapeutix